On November 4, 2026 Karyopharm Therapeutics Inc. (Nasdaq: KPTI) ("Karyopharm" or the "Company"), a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported that abstracts from two of its clinical trials evaluating selinexor in patients with myelofibrosis were selected for oral presentations at ASH (Free ASH Whitepaper) 2026. In addition, an abstract from a clinical trial evaluating selinexor in combination with other backbone therapies in multiple myeloma was selected for a poster presentation.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"New data from SENTRY continues to highlight the promising clinical activity achieved with the combination of selinexor plus ruxolitinib in patients with myelofibrosis, with ongoing benefit observed through week 48," said Reshma Rangwala, M.D., Ph.D., Chief Medical Officer and Head of Research of Karyopharm. "I am also encouraged by early data from the Phase 2 SENTRY-2 trial where selinexor is being evaluated as a monotherapy, with an optional add-on of a JAK inhibitor. Data from the 60 mg cohort of SENTRY-2 support monotherapy selinexor activity in JAKi-naïve myelofibrosis."
Phase 3 SENTRY 48 Week Data Oral Presentation Details – Myelofibrosis
Title: Updated results from the Phase 3 SENTRY trial investigating selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis
Publication Number: 526
Session Title: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Combining Forces Against Myelofibrosis
Presentation Time: December 13, 2026 from 10:15 a.m. CT to 10:30 a.m. CT
Phase 2 SENTRY-2 Monotherapy Data Oral Presentation Details – Myelofibrosis
Title: Phase 2 study evaluating selinexor monotherapy in patients with JAKi-naïve myelofibrosis
Publication Number: 244
Session Title: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Emerging Therapies and Approaches in MPN
Presentation Time: December 12, 2026 from 2:45 p.m. CT to 3:00 p.m. CT
Phase 1b/2 STOMP Arm 12 Poster Presentation Details – Multiple Myeloma
Title: Selinexor, mezigdomide, and dexamethasone (SMd) in patients with relapsed/refractory multiple myeloma (RRMM) who relapsed or are ineligible for T-cell–redirecting therapy: updated results from STOMP Arm 12
Publication Number: 2242
Session Title: 654. Multiple Myeloma: Pharmacologic Therapies: Poster I
Presentation Time: December 12, 2026 from 5:30 p.m. CT to 7:30 p.m. CT
About the Phase 3 SENTRY Trial
SENTRY (XPORT-MF-034; NCT04562389) is a Phase 3 clinical trial evaluating a once-weekly dose of 60 mg of selinexor in combination with ruxolitinib compared to placebo plus ruxolitinib in JAKi-naïve myelofibrosis patients with platelet counts >100 x 109/L (N=353). Patients were randomized 2-to-1 to the selinexor arm. The co-primary endpoints for this trial are spleen volume reduction ≥ 35% (SVR35) at week 24 and the average change in absolute total symptom score (Abs-TSS) over 24 weeks relative to baseline. The results from the Phase 3 SENTRY trial were presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting and were simultaneously published in the peer-reviewed Journal of Clinical Oncology. In addition, the results were presented at the 2026 European Hematology Association (EHA) (Free EHA Whitepaper) Congress, where the presentation was recognized as one of the six best abstracts at the meeting.
About the Phase 2 SENTRY-2 Trial
SENTRY-2 (XPORT-MF-044; NCT05980806) is a multicenter, open-label, Phase 2 study evaluating the efficacy of selinexor monotherapy (cohort 1: 60 mg once-weekly; n=29 per arm) in patients with JAKi-naïve myelofibrosis and thrombocytopenia (platelet count ≥50×109/L). Optional ruxolitinib, pacritinib, or momelotinib treatment (based on platelet count) could be added for patients whose SVR from baseline is <10% at Week 12 or <35% at Week 24. The primary endpoint is spleen volume reduction ≥35% (SVR35) at Week 24. Key secondary endpoints are safety and absolute total symptom score (Abs-TSS) at Week 24. Exploratory endpoints include changes in variant allele frequency (VAF) and bone marrow fibrosis.
About Myelofibrosis
Myelofibrosis is a rare blood cancer that affects approximately 20,000 patients in the United States and 19,000 patients in the European Union1. The disease causes bone marrow fibrosis (scarring in the bone marrow), which makes it difficult for the bone marrow to make healthy blood cells, splenomegaly (enlarged spleen), progressive anemia which often leads to symptoms like fatigue and weakness, and other disease associated symptoms including abdominal discomfort, pain under the left ribs, early satiety, night sweats and bone pain. The only approved class of therapies to treat myelofibrosis are JAK inhibitors, including ruxolitinib.
1. Clarivate/DRG (2023)
About STOMP Arm 12
Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP; NCT02343042) Arm 12 is evaluating the all-oral combination of selinexor, mezigdomide, and dexamethasone (SMd) in adults with triple-class exposed relapsed/refractory multiple myeloma with ≥2 prior lines of therapy and who had progressed after or were deemed ineligible for T-cell-redirecting therapy (TCRT). Phase 1 had 3 cohorts with the selinexor dose escalated from 40 mg once weekly to 60 mg on days 1, 8, and 15 of a 28-day cycle; mezigdomide is administered at 0.6 or 1.0 mg daily on days 1–21, and dexamethasone 40 mg is administered weekly. Responses are assessed by investigator using International Myeloma Working Group criteria, and safety is assessed per Common Terminology Criteria for Adverse Events (CTCAE) V5.0. Phase 1 objectives are to determine maximum tolerated dose and recommended Phase 2 dose (RP2D) of SMd; Phase 2 primary objectives are to determine objective response rate (ORR) and further characterize safety as per CTCAE V5.0 at the RP2D.
About XPOVIO (selinexor)
XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO (also known as NEXPOVIO in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO/NEXPOVIO is marketed in these respective ex-U.S. territories by Karyopharm’s partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high-unmet need cancer indications.
For more information about Karyopharm’s products or clinical trials, please contact the Medical Information department at: Tel: +1 (888) 209-9326; Email: [email protected]
XPOVIO (selinexor) is a prescription medicine approved:
In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd).
In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd).
SELECT IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Thrombocytopenia: Monitor platelet counts throughout treatment. Manage with dose interruption and/or reduction and supportive care.
Neutropenia: Monitor neutrophil counts throughout treatment. Manage with dose interruption and/or reduction and granulocyte colony‐stimulating factors.
Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, anorexia, and weight loss may occur. Provide antiemetic prophylaxis. Manage with dose interruption and/or reduction, antiemetics, and supportive care.
Hyponatremia: Monitor serum sodium levels throughout treatment. Correct for concurrent hyperglycemia and high serum paraprotein levels. Manage with dose interruption, reduction, or discontinuation, and supportive care.
Serious Infection: Monitor for infection and treat promptly.
Neurological Toxicity: Advise patients to refrain from driving and engaging in hazardous occupations or activities until neurological toxicity resolves. Optimize hydration status and concomitant medications to avoid dizziness or mental status changes.
Embryo‐Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with a female partner of reproductive potential, of the potential risk to a fetus and use of effective contraception.
Cataract: Cataracts may develop or progress. Treatment of cataracts usually requires surgical removal of the cataract.
Adverse Reactions
The most common adverse reactions (≥20%) in patients with multiple myeloma who receive XVd are fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract and vomiting. Grade 3‐4 laboratory abnormalities (≥10%) are thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia, and neutropenia. In the BOSTON trial, fatal adverse reactions occurred in 6% of patients within 30 days of last treatment. Serious adverse reactions occurred in 52% of patients. Treatment discontinuation rate due to adverse reactions was 19%.
The most common adverse reactions (≥20%) in patients with multiple myeloma who receive Xd are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection. In the STORM trial, fatal adverse reactions occurred in 9% of patients. Serious adverse reactions occurred in 58% of patients. Treatment discontinuation rate due to adverse reactions was 27%.
Use In Specific Populations
Lactation: Advise not to breastfeed.
For additional product information, including full prescribing information, please visit www.XPOVIO.com.
To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1‐888‐209‐9326 or FDA at 1‐800‐FDA‐1088 or www.fda.gov/medwatch.
(Press release, Karyopharm, NOV 4, 2026, View Source [SID1234674171])